Atea Pharmaceuticals, Inc. Share Repurchase Authorization
Atea Pharmaceuticals, Inc. (AVIR) had Share Repurchase Authorization of $25.00 million as of 2025-04-30, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Equity
srt:StockRepurchaseProgramAuthorizedAmount1 · last filed 2026-03-05
- 2025-04-30: Stock Repurchase Program Authorized Amount1 $25.00M.
| Period end | Stock Repurchase Program Authorized Amount1 |
|---|---|
| 2025-04-30 | $25.00M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |